Display options
Cite
Masson S, Persad R, Bahl A. Corrigendum to "HDR Brachytherapy in the Management of High-Risk Prostate Cancer". Adv Urol. 2016;2016:6345816doi: 10.1155/2016/6345816.
Masson, S., Persad, R., & Bahl, A. (2016). Corrigendum to "HDR Brachytherapy in the Management of High-Risk Prostate Cancer". Advances in urology, 20166345816. https://doi.org/10.1155/2016/6345816
Masson, Susan, et al. "Corrigendum to "HDR Brachytherapy in the Management of High-Risk Prostate Cancer"." Advances in urology vol. 2016 (2016): 6345816. doi: https://doi.org/10.1155/2016/6345816
Masson S, Persad R, Bahl A. Corrigendum to "HDR Brachytherapy in the Management of High-Risk Prostate Cancer". Adv Urol. 2016;2016:6345816. doi: 10.1155/2016/6345816. Epub 2016 Nov 21. PMID: 28042293; PMCID: PMC5136636.
Copy Download .nbib Format: NLM
Share it on

Adv Urol. 2016;2016:6345816. doi: 10.1155/2016/6345816. Epub 2016 Nov 21.

Corrigendum to "HDR Brachytherapy in the Management of High-Risk Prostate Cancer".

Advances in urology

Susan Masson, Raj Persad, Amit Bahl

Affiliations

  1. Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation Trust, Bristol BS2 8ED, UK.
  2. Department of Urology, University Hospitals Bristol NHS Foundation Trust, Bristol BS2 8HW, UK.

PMID: 28042293 PMCID: PMC5136636 DOI: 10.1155/2016/6345816

Abstract

[This corrects the article DOI: 10.1155/2012/980841.].

References

  1. Adv Urol. 2012;2012:980841 - PubMed

Publication Types